Butyrate modulating effects on pro-inflammatory pathways in human intestinal epithelial cells by Elce, A. et al.
Beneficial Microbes, 2016; ##(##): 1-7 
Wageningen Academic 
P u b l i s h e r s
ISSN 1876-2883 print, ISSN 1876-2891 online, DOI 10.3920/BM2016.0197 1
1. Introduction
Among short-chain fatty acids produced by colonic dietary 
fibre fermentation, butyrate has received most attention 
for its effects on gut health (Hamer et al., 2008). The 
functions of butyrate ranges from being an energy source 
for colonocytes to be a key mediator of anti-inflammatory 
and anti-tumorigenic effects (Guilloteau et al., 2010). 
Indeed, a reduced number of butyrate-producing bacteria 
was found in colon of patients with ulcerative colitis (UC) 
and colon cancer (Frank et al., 2007; Wang et al., 2012) 
and experimental and clinical studies demonstrated the 
beneficial effects of butyrate treatment (mainly by enema) 
on chronic intestinal inflammatory diseases (Canani et al., 
2011; Chen et al., 2014; Felice et al., 2015). In addition, 
sodium butyrate accelerates maturation and modulates 
several functions of the small intestine (Gorka et al., 2014). 
Our group successfully treated with oral butyrate a child 
affected by the severe congenital chloride diarrhoea (CCD) 
obtaining a normalisation of stool pattern and of serum 
and faecal electrolytes balance. This was due to the pro-
absorptive effect induced by butyrate on Na+, Cl-, and 
K+ intestinal transport demonstrated by rectal dialysis 
and to the trophic effect of butyrate on intestinal mucosa 
(Canani et al., 2004). Later, we confirmed this result on 
other patients with CCD, demonstrating that the butyrate 
effect depends on the solute carrier family 26 member 3 
(SLC26A3) genotype, since it enhances the expression of 
the SLC26A3 disease gene (Canani et al., 2013), and thus, 
a significant therapeutic effect was obtained in patients 
bearing mutations that permit the correct topogenesis of the 
protein at membrane level (Canani et al., 2013). In fact, the 
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Abstract
Butyrate acts as energy source for intestinal epithelial cells and as key mediator of several immune processes, modulating 
gene expression mainly through histone deacetylation inhibition. Thanks to these effects, butyrate has been proposed for 
the treatment of many intestinal diseases. Aim of this study was to investigate the effect of butyrate on the expression of 
a large series of target genes encoding proteins involved in pro-inflammatory pathways. We performed quantitative real-
time-PCR analysis of the expression of 86 genes encoding proteins bearing to pro-inflammatory pathways, before and 
after butyrate exposure, in primary epithelial cells derived from human small intestine and colon. Butyrate significantly 
down-regulated the expression of genes involved in inflammatory response, among which nuclear factor kappa beta, 
interferon-gamma, Toll like 2 receptor and tumour necrosis factor-alpha. Further confirmations of these data, including 
studies at protein level, would support the use of butyrate as effective therapeutic strategy in intestinal inflammatory 
disorders.
Keywords: inflammation, membrane carrier, short chain fatty acids
7 online  ARTICLE IN PRESS
ht
tp
://
w
w
w
.w
ag
en
in
ge
na
ca
de
m
ic
.c
om
/d
oi
/p
df
/1
0.
39
20
/B
M
20
16
.0
19
7 
- S
un
da
y,
 S
ep
te
m
be
r 2
4,
 2
01
7 
1:
53
:0
4 
A
M
 - 
G
öt
eb
or
gs
 U
ni
ve
rs
ite
t I
P 
A
dd
re
ss
:1
30
.2
41
.1
6.
16
 
A. Elce et al.
2 Beneficial Microbes ##(##)
main molecular mechanism of butyrate is the modulation of 
gene expression by the inhibition of chromatin-remodelling 
activity of histone deacetylases (Donohoe et al., 2012). 
As consequence, butyrate stimulates the proliferation of 
normal colonocytes whereas it inhibits the proliferation 
of cancer cells (Guilloteau et al., 2010; Hamer et al., 2008), 
but its main effect is the anti-inflammatory activity, due to 
the down-regulation of genes encoding pro-inflammatory 
modulators (Felice et al., 2015). However, a systematic 
analysis of genes whose expression is modulated by butyrate 
has not been performed so far. We analysed gene expression 
changes induced by butyrate in primary human intestinal 
epithelial cells either from small intestine and from colon 
on a series of genes encoding proteins involved in different 
inflammatory pathways.
2. Materials and methods
Human small intestine epithelial cells culture
Normal human small intestine epithelial cells (HSIEpiC) 
from a single donor were purchased by Innoprot (Bizkaia, 
Spain). Cells were cultured in epithelial pro-conditioned 
medium (Innoprot) and placed in CELL+ T 25 flasks 
(Sarstedt, Nümbrecht, Germany). Flasks were coated with 
collagen type I bovine solution 3 mg/ml (Sigma, St. louis, 
MO, USA), according to the manufacturer’s indications. 
Medium was changed daily. At confluence of 60%, cells 
were passed in new flasks after count, using Invitrogen Cell 
Counters (Invitrogen, Paisley, UK). Trypan blue exclusion 
test was used to establish total viable cells number and 
percentage of viability. About 3,000 viable cells/cm2 per 
flask were placed. At the sixth day of culture and at the 
confluence of 60-80%, cells were incubated with 5 mM 
of sodium butyrate (Sigma) for 24 h. Such conditions 
had been previously revealed as optimal in modulating 
the expression of either SLC26A3 and cystic fibrosis 
transmembrane regulator (CFTR) genes by several human 
primary cells (Canani et al., 2013). In our previously studies, 
using primary intestinal cells and patient-derived nasal 
cells, we performed dose and time dependent curves for 
some genes responsive to butyrate treatment like the 
members of SLC family genes SLC26A3 and SLC26A6. 
We observed that the best response for gene expression 
modulation was obtained with an exposure of 5 mM of 
sodium butyrate for 24 h (Canani et al., 2013). In the 
same study we have administered 100 mg/kg/day to seven 
children affected by CCD. We demonstrated a genotype-
dependency for butyrate therapeutic efficacy in CCD and 
postulated that the positive effect may be related not only to 
a SLC26A3 and A6 up-regulation, but also to a modulation 
of intestinal inflammation. In 2012, Donohoe et al. found 
that a concentration of 5 mM of sodium butyrate is able to 
explicate the HDAC inhibition, mediated by intracellular 
accumulation of butyrate on HCT116 colon carcinoma 
cell nucleus. This dose reflect the physiological amount 
detected in the colon lumen after colostomy (Luhrs et al., 
2002). Starting from these data, we have chosen to study 
the effect of a concentration of 5 mM of butyrate for 24 h 
on specific inflammation-related targets.
Human colonic cells culture
Human colon primary cells T150 were purchased by 
Celprogen (Torrance, CA, USA), and seeding according 
to the manufacturer’s. Cells were placed in CELL+ T 25 
flasks (Sarstedt) and maintained in culture with human 
colon cell culture complete growth serum free medium 
(Celprogen). Initial seeding density was 3,000 viable cells/
cm2 per flask. Medium was changed daily. At the sixth 
day of culture and at the confluence of 60-80%, cells were 
incubated with 5 mM of sodium butyrate (Sigma) for 24 h.
RNA isolation and cDNA preparation
Total RNA was extracted using TRIzol method (Invitrogen). 
cDNA was transcribed with transcriptor first strand 
cDNA synthesis kit (Roche, Basel, Switzerland), following 
manufacture instructions, starting from an amount of 
1 µg of total RNA per reaction. Total RNA amount was 
quantified with Nanodrop 1000 spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA, USA).
Real time array design
Real time array was designed according to RealTime 
ready Custom Panel (Roche). It consists of LightCycler 
480 Multiwell Plates 96 containing pre-plated qPCR assays 
pre tested and validated on human cDNA samples. Each 
well of a Real Time ready custom panel 96 contains two 
primers (8 pM of each primer) and one Universal Probe 
Library probe (4 pM). Each assay includes primers and a 
Universal Probe Library probe, which is a short fluorescein 
amidite (FAM)-labelled hydrolysis probe containing locked 
nucleic acid. Taqman chemistry was adopted for the assay. 
We analysed a set of transcripts of 83 genes involved 
in inflammation pathways selecting the most known 
modulators of inflammation or known targets of short 
chain acid modulation. A full list of all targets analysed is 
available in Supplementary Table S1 that reports also the 
Entrez name of each gene. Three housekeeping genes, i.e. 
beta actin, glucose-6-phosphate dehydrogenase (G6PD) 
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
were included in the panel as internal control.
Real Time PCR reaction and analysis of results
PCR reaction was performed according to Roche’s Real 
Time ready panel instructions on Light Cycler 480 real 
time system. Briefly, a mix composed by the Light Cycler 
480 probes master (2×), 2 µl of cDNA diluted 1:5 and water, 
for a total volume of 20 µl of reaction was added in every 
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well of the plate. PCR program, recommended by Roche, is 
available in Supplementary Table S2. Real time PCR array 
analysis was carried out using relative Cp values, calculated 
from expression levels of the reference genes. Finally, gene 
expression levels for each sample were normalised to the 
expression level of the best housekeeping gene within a 
given sample (ΔCp); the relative expression of each gene 
before and after butyrate treatment was calculated in order 
to estimate ΔΔCp (where ΔΔCp corresponds to the increase 
in the threshold cycle of the target gene respect to the 
increase in the threshold cycle of the housekeeping gene), 
according to Pfaffl et al. (2001). The final quantification 
value for each gene indicated the relative change (fold 
increase) of gene expression in the target gene compared 
to the control, for each sample.
Statistical analysis
To identify pathways significantly modulated by butyrate, 
we analysed our data with Ingenuity Pathway Analysis 
(IPA) (Ingenuity ®Systems; Qiagen Bioinformatics, Aarhus, 
Denmark). A P-value <0.05 and a fold change <2 or >2 was 
considered significant for expression analysis. Differentially 
expressed genes before and after butyrate treatment were 
imported into IPA and the top five canonical pathways 
were analysed. The canonical pathway analysis identified 
the molecular pathways from the IPA library of canonical 
pathways that were most significant to the dataset. Z-score 
represents the significance of changes in molecular network 
determined experimentally by observed gene expression 
levels and function annotation data stored in the Ingenuity 
Knowledge Base of IPA. These relationships are associated 
with a direction of change that is either activating (z-score 
≥2) or inhibiting (z-score ≤-2).
3. Results
The butyrate treatment of human epithelial cells from 
colon and from small intestine did not modify the 
transcription of 55/86 (64%) genes tested (Supplemental 
Table S3) whereas, it significantly modified the levels of 
transcription (<2 folds/>2 folds) of 31/86 (36%) genes. For 
most of such genes, the treatment significantly reduced the 
expression (from 2 to 32 folds), while it enhanced (from 2 
to 8 folds) the expression of only few genes. Figure 1, Table 
1 and Supplemental Figure S1 show the effect of butyrate 
treatment on the 31 genes whose transcription levels were 
significantly modified.
As shown in Figure 1, in epithelial colon cells butyrate 
treatment significantly inhibited the expression of 14 genes. 
For 8/14 of them (i.e. MAPK13, NFKB1A, NFKB1, CXCL1, 
CXCL2, MAPK3, AKT1, CCL2), we obtained a significant 
inhibition of expression either in colon and in small intestine 
cells; for 3/14 of them (i.e. CXCL10, CXCL6, CXCL3), 
we observed a significant reduction of gene expression 
in colon cells while, in cells derived from small intestine, 
we observed a significant enhancement of expression and 
finally, for the remaining 3/14 (i.e. TRL2, SERPINA1 and 
TNF) the butyrate caused a significant reduction of gene 
expression in colon cells while in small intestine cells we did 
not observe any change of gene expression. Again in colon 
cells (Figure 1), butyrate treatment significantly enhanced 
the expression of 2 genes, for 1 of which (i.e. TIMP1) we 
observed a down-regulation of gene expression in cells 
from small intestine; for the other (i.e. SERPINA2) we did 
not observe any change in small intestine cells. In addition, 
for 13 other genes (i.e. IL-6, CSF3, TLR4, ICAM1, AKT2, 
VEGFA, IL-12A, AKT3, MAPK10, MVP, CXCL8, IL-1B and 
-40
-35
-30
-25
-20
-15
-10
-5
0
5
10
15
CXCL10
MAPK13
CXCL6
TLR2
NFKBIA
NFKB1
CXCL1
CXCL2
CXCL3
MAPK3
AKT1
CCL2
SERPINA1
TNF
TIMP1
SERPINA2
IL6 CSF3
TLR4
ICAM1
AKT2
VEGFA
IL12A
AKT3
MAPK10
MVP
CXCL8
IL1B
CAMP
IL18
IGFBP3
Ex
pr
es
sio
n l
ev
el 
(fo
ld 
ch
an
ge
)
Colon
Small intestine
Figure 1. mRNA expression of transcripts related to inflammation modulated by in vitro treatment with butyrate in human colon 
and small intestinal cells.
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CAMP), the treatment with butyrate significantly reduced 
the levels of expression only in epithelial small intestine 
cells with no effects in colon cells, while for 2 genes (i.e. 
IL-18 and IGFBP3), the treatment significantly enhanced 
gene expression in small intestine cells with no effects in 
colon cells. Then, using the IPA program, we evaluated 
the global effect of butyrate treatment on several pathways 
either in colon and in small intestine epithelial cells (Table 
2). The results were fully concordant between the two 
types of cells: in fact, the treatment significantly down-
regulated the following 5 pathways in both the types of cells: 
triggering receptor expressed on myeloid cells (TREM-1) 
signalling; production of nitric oxide (NO) and reactive 
oxygen species (ROS); acute phase response signalling; 
interleukin 6 (IL-6) signalling; high-mobility group box-1 
(HMGB1) signalling. While, the treatment significantly up-
regulated the peroxisome proliferator-activated receptor 
alpha (PPARα)/retinoid X receptor alpha (RXR) activation 
and the liver X receptor (LXR)/RXR activation pathways, 
again with a concordant effect in the two types of cells.
Table 1. List of 31 transcripts whose expression is modulated by butyrate in human epithelial colon and in small intestinal primary 
cells (fold change <2 or >2, P<0.05).
Symbol Entrez Gene Name Fold change 
Colon
P-value Fold change 
Small intestine
P-value
CXCL10 chemokine (C-X-C motif) ligand 10 -22.9 0.002 8.3 0.001
MAPK13 mitogen-activated protein kinase 13 -11.2 0.003 -6.0 0.001
CXCL6 chemokine (C-X-C motif) ligand 6 -9.5 0.0015 3.4 0.005
TLR2 toll-like receptor 2 -7.4 0.003
NFKBIA nuclear factor of kappa light polypeptide gene enhancer in 
B-cells inhibitor alpha
-7.3 0.001 -3.2 0.001
NFKB1 nuclear factor of kappa light polypeptide gene enhancer in 
B-cells 1
-5.4 0.002 -10.3 0.0015
CXCL1 chemokine (C-X-C motif) ligand 1 -4.5 0.001 -7.8 0.001
CXCL2 chemokine (C-X-C motif) ligand 2 -4.4 0.002 -12.0 0.003
CXCL3 chemokine (C-X-C motif) ligand 3 -3.9 0.001  2.5 0.0015
MAPK3 mitogen-activated protein kinase 3 -3.2 0.001 -5.4 0.0008
AKT1 v-akt murine thymoma viral oncogene homolog 1 -3.0 0.004 -8.4 0.002
CCL2 chemokine (C-C motif) ligand 2 -3.0 0.001 -15.0 0.003
SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 1
-2.4 0.0008
TNF tumour necrosis factor -2.4 0.004
TIMP1 TIMP metallopeptidase inhibitor 1 3.1 0.001 -4.6 0.001
SERPINA2 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 2
3.8 0.001  
IL-6 interleukin 6 -32.2 0.0009
CSF3 colony stimulating factor 3 -9.4 0.008
TLR4 toll-like receptor 4 -8.7 0.001
ICAM1 intercellular adhesion molecule 1 -5.0 0.003
AKT2 v-akt murine thymoma viral oncogene homolog 2 -4.5 0.001
VEGFA vascular endothelial growth factor A -4.4 0.001
IL-12A interleukin 12 A -3.4 0.001
AKT3 v-akt murine thymoma viral oncogene homolog 3 -3.2 0.003
MAPK10 mitogen-activated protein kinase 10 -3.0 0.0015
MVP major vault protein -2.9 0.001
CXCL8 chemokine (C-X-C motif) ligand 8 -2.8 0.0008
IL-1B interleukin 1, beta -2.7 0.001
CAMP cathelicidin antimicrobial peptide -2.6 0.001
IL-18 interleukin 18 2.2 0.001
IGFBP3 insulin-like growth factor binding protein 3 4.2 0.0008
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4. Discussion and conclusions
Butyrate significantly modulates (mainly inhibiting) 
the expression of 31 genes encoding proteins with pro-
inflammatory activity. Although there are some differences 
between colon and small intestine epithelial cells, the 
analysis of the data using the IPA program (Zhou et al., 
2013) showed a complete overlapping of involved pathways 
between the two types of cells. Butyrate significantly down-
regulates the TREM-1 signalling pathway that during 
infections leads to the activation of myeloid cells and 
promotes the synthesis and the release of pro-inflammatory 
cytokines (Schenk et al., 2007). Either in mouse models of 
inflammatory bowel disease (IBD) and in humans, such 
pathway is significantly up-regulated (Mueller, 2012) and 
its activity is related to disease activity (Goncalves et al., 
2013). The down-regulation of TREM-1 pathway explains 
the beneficial effects of butyrate on IBD (Canani et al., 2011) 
reinforcing the potential of a novel therapy that seems to be 
free from toxic effects (Steppe et al., 2014). Furthermore, 
butyrate down-regulates the NO and ROS pathways, 
explaining the known effects of butyrate against oxidative 
stress (Ock et al., 2012). Such pathway is involved in a large 
series of human chronic diseases, including Helicobacter 
pylori-associated atrophic gastritis and gastric, colon, lung, 
prostate, bladder and breast cancer (Biasi et al., 2013).
Furthermore, oxidative stress is a key mechanism in the 
pathogenesis of Crohn’s disease (CD) since it dramatically 
impairs the immune response toward dietary antigens and 
toward commensal microbiota (Fuyitake et al., 2013). In 
fact, molecular treatments to contrast the oxidative stress 
are a primary aim in the field of such diseases (Ito et al., 
2004). The acute phase response signalling resulted also 
down-regulated by butyrate. This pathway has a relevant 
role in the pathogenesis of either adult UC, for which it 
has been recently demonstrated the beneficial effect of 
enteric microbiota (Chen et al., 2014) and in paediatric 
CD and a massive release of pro-inflammatory cytokines 
(the cytokine storm) is a typical marker of acute IBD (Biasi 
et al., 2013). The IL-6 signalling pathway, that in turn is 
down-regulated by butyrate, has a key role in adaptive 
immunity and in maintaining chronic inflammation in IBD. 
In fact, serum IL-6 is a known biochemical marker of IBD 
activity and outcome and the inhibition of such pathway was 
successfully used in the treatment of CD (Ito et al., 2004). 
In addition, both in mice and in humans IL-6 is critical in 
creating a tumour-promoting microenvironment (Waldner 
and Neurath, 2014).
Finally, among pathways down-regulated by butyrate 
there is the HMGB1 one; HMGB1 is a member of the 
high-mobility group superfamily, with a regulating role 
in biological processes like transcription, DNA repair, 
differentiation and development (Czura et al., 2001). In 
particular, HMGB1 has a cytokine-like role: it is massively 
released from cells undergoing necrosis and mediates late 
lethal systemic inflammation (Palumbo and Bianchi, 2004). 
Recently, a role of HMGB1 in the pathogenesis of IBD in 
child was revealed and faecal levels of the protein became 
an effective marker for IBD diagnosis and monitoring (Vitali 
et al., 2011). Interestingly, our data confirm the observation 
that butyrate suppresses HMGB1 protein production in 
liver tissue of rats with acute liver failure (Yang et al., 2014) 
and in several organs of rats during sepsis (Zhang et al., 
2007).
A second group of effects of butyrate involves pathways that 
regulate lipid absorption and metabolism, in agreement 
with the known effect of butyrate in providing feeding 
and energy sources for colonocytes and in regulating some 
key points of lipid metabolism (Berni Canani et al., 2011). 
In fact, butyrate up regulates the PPAR alpha/RXR alpha 
activation and the LXR/RXR activation pathways in either 
colon and in small intestine cells. Both these pathways 
have key roles in the regulation of human metabolism. The 
peroxisome proliferator-activated receptor (PPAR) is a main 
regulator of the lipid metabolism in peripheral tissue, like 
liver and skeletal muscle and contributes to enhance fatty 
acid oxidation in intestinal cells. Such effects dramatically 
reduce post-prandial lipidemia, mainly triglycerides, so 
that PPAR is becoming a target for therapy of postprandial 
Table 2. Main pathways regulated by butyrate in in human epithelial colon and in small intestinal primary cells.
Pathway Effect Colon z-score Colon P-value Small intestine 
z-score
Small intestine 
P-value
TREM1 signalling downregulated -2.646 3.76E-11 -2.496 8.19E-26
Production of NO and ROS downregulated -2.828 5.28E-10 -3.464 3.27E-16
Acute phase response signalling downregulated -2.646 1.17E-8 -2.714 1.55E-13
IL-6 signalling downregulated -2.449 3.83E-8 -3.051 6.0E-19
HMGB1 signalling downregulated -2.449 4.69E-8 -3.207 2.69E-22
PPARα/RXRα activation upregulated 2.0 1.87E-5 2.236 2.45E-04
LXR/RXR activation upregulated 2.236 2.45E-04 2.330 4.19E-12
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lipidemia in obese subjects (Kimura et al., 2013). Liver X 
receptors (LXR) are transcription factors that regulate 
cholesterol, bile acid, triglyceride and glucose homeostasis 
(Baronowski, 2008) but, more interestingly, LXR seems 
to modulate also intestinal lipid absorption and intestinal 
inflammation (Gao et al., 2013). Several studies in mice 
recognised the role of LXR in protecting from high fat 
diet-induced obesity and insulin resistance (Stojcev et al., 
2013). Thus, the activation of such pathways by butyrate 
has a relevant impact in the control of lipid metabolism.
Taken together, the effects of butyrate in the regulation 
of gene expression at intestinal level delineate the role of 
a substance that contributes to inhibit acute and chronic 
inflammatory processes (most of which related to chronic 
intestinal diseases in humans) and maintain the metabolic 
homeostasis of intestinal cells, confirming the effects 
observed in vivo in several human diseases (Canani et al., 
2011; Hamer et al., 2008). Such data encourage further 
studies (also including the quantitative analysis of proteins) 
aimed to confirm the anti-inflammatory effects of butyrate 
and clinical trials on large populations to standardise the 
use of such molecule in the prevention and treatment of 
human inflammatory intestinal diseases.
Supplementary material
Supplementary material can be found online at https://
doi.org/10.3920/BM2016.0197.
Table S1. Full list of all targets analysed in this study.
Table S2. Real time PCR program adopted in this study.
Table S3. List of targets whose level of expression was 
observed as unchanged after butyrate exposure of colon 
and small intestine.
Figure S1. Heat map of transcripts modulated by 5 mM 
butyrate exposure of human colon and small intestinal 
cells for 24 h.
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